Data

N-3 fatty acids for improvement in Respiratory Outcomes - the N3RO Trial

Health Data Australia Contributor Records
gould, jacqueline ; Makrides, Maria ; Health Translation SA Enquiries
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58138/M4RW-JC89&rft.title=N-3 fatty acids for improvement in Respiratory Outcomes - the N3RO Trial&rft.identifier=http://doi.org/10.58138/M4RW-JC89&rft.publisher=South Australian Health and Medical Research Institute (SAHMRI)&rft.description=This dataset includes 1244 preterm infants born at less than 29 weeks' gestation, within 3 days of first enteral feed were randomised (622 per group) to receive an enteral emulsion containing DHA or a control emulsion without DHA. The DHA emulsion provided 60 mg/kg/day of DHA. The study emulsions continued to 36 weeks' postmenstrual age (PMA). The primary outcome was bronchopulmonary dysplasia, as assessed by the requirement for supplemental oxygen and/or assisted ventilation at 36 weeks' PMA. File type is .PDF.&rft.creator=gould, jacqueline &rft.creator=Makrides, Maria &rft.creator=Health Translation SA Enquiries &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000503820&rft.coverage=South Australia Victoria Queensland Western Australia New South Wales&rft_subject=Infant and Child Health&rft_subject=Respiratory Diseases&rft_subject=Reproduction&rft_subject=FOS: Medical biotechnology&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

This dataset includes 1244 preterm infants born at less than 29 weeks' gestation, within 3 days of first enteral feed were randomised (622 per group) to receive an enteral emulsion containing DHA or a control emulsion without DHA. The DHA emulsion provided 60 mg/kg/day of DHA. The study emulsions continued to 36 weeks' postmenstrual age (PMA). The primary outcome was bronchopulmonary dysplasia, as assessed by the requirement for supplemental oxygen and/or assisted ventilation at 36 weeks' PMA. File type is .PDF.

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Related People

Spatial Coverage And Location

text: South Australia Victoria Queensland Western Australia New South Wales

Subjects
FOS: Medical biotechnology | Infant and Child Health | Reproduction | Respiratory Diseases |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Health Translation SA Enquiries

Other : enquiries@healthtranslationsa.org.au

National Health and Medical Research Council

Crossref Funder ID : https://doi.org/10.13039/501100000925

Identifiers
Similar data you may be interested in: